A federal jury in Delaware has ordered a unit of Takeda Pharmaceutical Co. to pay Bayer HealthCare LLC $155 million in damages for infringing a patent related to Bayer’s hemophilia treatment.

According to court records, the Wilmington jury in its Feb. 5 verdict rejected Baxalta’s arguments that Bayer’s patent was invalid after six days of trial in the case, which was filed in December 2016, when Baxalta was still owned by Irish biopharmacuetical firm Shire. The jury applied a 17.7 percent royalty rate to a base of nearly $873 million to reach its total damage award.